Evaluation of Dynamic Balance After Recovery From COVID 19 Disease

effect of post covid-19 on dynamic balance in patients after recovery from covid-19 disease.

Study Overview

• Status: Completed
• Conditions: COVID-19 Respiratory Infection
• Intervention / Treatment: Other: biodex balance system

Detailed Description

effect of post covid-19 on dynamic balance in patients after recovery from COVID disease.

patients will treated with medical protocol of COVID 19 an out-patient clinic , and followed up by the chest specialist . The balance tests of the patients were performed 2 to 14 weeks after their recovery from the disease, which was confirmed by the evaluations of the COVID staff and negative polymerase chain reaction test.the patients will evaluated using questionnaires. First, the question will whether feeling in balance in the daily life or not. The answer will classified as "yes"or "no". Second, asked to fill "Dizziness Handicap Inventory"(DHI), which is a multidimensional self- assessment scale created to evaluate the effects of dizziness and balance problems on the quality of life as well as the level of disability of the patients. Assess balance , which consists of a movable balance platform that provides up to 20 of surface tilt in a 360 range of motion. The platform is interfaced with computer software that enables the device to serve as an objective assessment of balance . The measure of postural stability includes the overall (OA), the anteroposterior (AP) and the mediolateral (ML) stability scores. A high score in the OA index indicates poor balance. The OA stability score is believed to be the best indicator of the overall ability of the patient to balance the platform

• Study Type: Observational
• Enrollment (Actual): 25

Contacts and Locations

Study Locations

• Egypt
  • Giza
    • El-Sheikh Zayed City, Giza, Egypt, 1133
      • October 6 u

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: N/A

• Sampling Method: Probability Sample

Study Population

25 patients (males and females) who recovered from Covid-19 disease will be selected from 6 october unversity Hospital outpatient Clinic their age from 30 -40 years old and 25 healthyage and gender matched (males and females

Description

Inclusion Criteria:

• 25post COVID-19 patients suffering from inbalance.
• Age will be ranged from 30 to 40 years old.
• Body mass index (BMI) will be ranged from 25 to 35 Kg/m2.
• Diagnosed as COVID-19 patients with a positive reverse transcription polymerase chain reaction (RT-PCR) result of SARS-CoV-2, or typical computerized tomography (CT) evidence of viral pneumonia.
• All enrolled patients with moderate covid-19 infection.

Exclusion Criteria:

• Severe disease or hospitalization at intensive care units will excluded from the study.
• Patients with previous hearing problems or balance disorders.
• Patients who had ear surgery, cardiovascular and circulatory problems,.
• Patients with orthopedic problems in the lower extremities due to other problems
• Patients with Any history of neurological or psychiatric disease, severe visual or auditory impairments.
• Diabetic patients.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
overall (OA), the anteroposterior (AP) and the Medio lateral (ML) stability scores	A high score in the OA index indicates poor balance. The OA stability score is believed to be the best indicator of the overall ability of the patient to balance the platform	2 to24 WEEKS after their recovery from the disease

Collaborators and Investigators

• Sponsor: October 6 University

Study record dates

Study Major Dates

• Study Start (Actual): February 20, 2022
• Primary Completion (Actual): December 30, 2022
• Study Completion (Actual): March 21, 2023

Study Registration Dates

• First Submitted: April 11, 2023
• First Submitted That Met QC Criteria: April 11, 2023
• First Posted (Actual): April 14, 2023

Study Record Updates

• Last Update Posted (Actual): April 19, 2023
• Last Update Submitted That Met QC Criteria: April 15, 2023
• Last Verified: April 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; COVID-19; Respiratory Tract Infections
• Other Study ID Numbers: P.T.REC/012/003590

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No